$ANIP
ANI PHARMACEUTICALS INC

2011 Q3 Form 10-Q Financial Statement

#000110465911062750 Filed on November 09, 2011

View on sec.gov

Income Statement

Concept 2011 Q3 2010 Q3
Revenue $182.8K $51.33K
YoY Change 256.09% 413.31%
Cost Of Revenue $0.00
YoY Change
Gross Profit $50.00K
YoY Change 400.0%
Gross Profit Margin 97.41%
Selling, General & Admin $1.680M $1.530M
YoY Change 9.8% 1.32%
% of Gross Profit 3060.0%
Research & Development $11.50M $9.716M
YoY Change 18.36% 188.31%
% of Gross Profit 19432.18%
Depreciation & Amortization $35.67K $41.00K
YoY Change -13.0% 2.5%
% of Gross Profit 82.0%
Operating Expenses $11.50M $9.716M
YoY Change 18.36% 97.88%
Operating Profit -$13.03M -$11.24M
YoY Change 15.91% 129.39%
Interest Expense $172.0K $172.0K
YoY Change 0.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$12.73M -$11.59M
YoY Change 9.84% 81.95%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.73M -$11.59M
YoY Change 9.84% 81.95%
Net Earnings / Revenue -6964.5% -22578.95%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.390M -$5.854M
COMMON SHARES
Basic Shares Outstanding 17.41M shares 71.19M shares
Diluted Shares Outstanding 17.41M shares

Balance Sheet

Concept 2011 Q3 2010 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $69.60M $35.50M
YoY Change 96.06% 168.94%
Cash & Equivalents $69.60M $35.53M
Short-Term Investments
Other Short-Term Assets $900.0K $1.200M
YoY Change -25.0% 20.0%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $70.50M $36.70M
YoY Change 92.1% 158.45%
LONG-TERM ASSETS
Property, Plant & Equipment $900.0K $600.0K
YoY Change 50.0% -14.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.400M $3.300M
YoY Change 3.03% 3200.0%
Other Assets $100.0K $100.0K
YoY Change 0.0% -88.89%
Total Long-Term Assets $4.400M $4.100M
YoY Change 7.32% 127.78%
TOTAL ASSETS
Total Short-Term Assets $70.50M $36.70M
Total Long-Term Assets $4.400M $4.100M
Total Assets $74.90M $40.80M
YoY Change 83.58% 155.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.000M $4.500M
YoY Change 33.33% 28.57%
Accrued Expenses $4.200M $2.600M
YoY Change 61.54% 116.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.200M
YoY Change
Total Short-Term Liabilities $11.50M $7.100M
YoY Change 61.97% 47.92%
LONG-TERM LIABILITIES
Long-Term Debt $19.20M $18.40M
YoY Change 4.35%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $19.20M $18.40M
YoY Change 4.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.50M $7.100M
Total Long-Term Liabilities $19.20M $18.40M
Total Liabilities $30.70M $25.50M
YoY Change 20.39% 431.25%
SHAREHOLDERS EQUITY
Retained Earnings -$210.6M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $44.10M $15.30M
YoY Change
Total Liabilities & Shareholders Equity $74.90M $40.80M
YoY Change 83.58% 155.0%

Cashflow Statement

Concept 2011 Q3 2010 Q3
OPERATING ACTIVITIES
Net Income -$12.73M -$11.59M
YoY Change 9.84% 81.95%
Depreciation, Depletion And Amortization $35.67K $41.00K
YoY Change -13.0% 2.5%
Cash From Operating Activities -$12.58M -$10.85M
YoY Change 15.94% 191.67%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K -$10.00K
YoY Change 1000.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$110.0K -$10.00K
YoY Change 1000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 45.16M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -12.58M -10.85M
Cash From Investing Activities -110.0K -10.00K
Cash From Financing Activities 45.16M 0.000
Net Change In Cash 32.47M -10.86M
YoY Change -398.99% -251.04%
FREE CASH FLOW
Cash From Operating Activities -$12.58M -$10.85M
Capital Expenditures -$110.0K -$10.00K
Free Cash Flow -$12.47M -$10.84M
YoY Change 15.04% 191.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Fair Value Option Changes In Fair Value Gain Loss
FairValueOptionChangesInFairValueGainLoss
-1687916 USD
CY2010Q3 us-gaap Interest Expense
InterestExpense
172000 USD
CY2010Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
526022 USD
CY2010Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4864217 USD
CY2010Q4 us-gaap Assets
Assets
44766650 USD
CY2010Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
99937 USD
CY2010Q4 us-gaap Long Term Investments
LongTermInvestments
3405807 USD
CY2010Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
635776 USD
CY2010Q4 us-gaap Assets Current
AssetsCurrent
40625130 USD
CY2010Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2469879 USD
CY2011Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210590243 USD
CY2010Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165630644 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38155251 USD
CY2010Q4 us-gaap Liabilities
Liabilities
25619528 USD
CY2010Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
17436201 USD
CY2010Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8183327 USD
CY2010Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1111132 USD
CY2010Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1681956 USD
us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
286000 USD
CY2010Q3 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
286000 USD
CY2010Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss
FairValueOptionChangesInFairValueGainLoss
103000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
5466 USD
us-gaap Costs And Expenses
CostsAndExpenses
32771153 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
128967 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4841619 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27800567 USD
CY2010Q3 us-gaap Costs And Expenses
CostsAndExpenses
11291508 USD
CY2010Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
41000 USD
CY2010Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1534417 USD
CY2010Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9716091 USD
us-gaap Revenues
Revenues
2331205 USD
us-gaap Royalty Revenue
RoyaltyRevenue
2279335 USD
us-gaap Revenue From Grants
RevenueFromGrants
51870 USD
CY2010Q3 us-gaap Revenues
Revenues
51331 USD
CY2010Q3 us-gaap Royalty Revenue
RoyaltyRevenue
51331 USD
CY2010Q3 us-gaap Investment Income Net
InvestmentIncomeNet
5466 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64092806 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94468428 shares
CY2010Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71194180 shares
CY2011Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104439220 shares
us-gaap Interest Expense
InterestExpense
516083 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31588892 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28934 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
2250 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3165012 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-953749 USD
us-gaap Interest Paid
InterestPaid
344000 USD
bpax Fair Value Adjustment Convertible Notes Payable
FairValueAdjustmentConvertibleNotesPayable
-1687916 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
57195 USD
us-gaap Share Based Compensation
ShareBasedCompensation
751790 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
804 USD
us-gaap Interest Paid
InterestPaid
344000 USD
CY2010Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35526017 USD
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29858465 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
31444948 USD

Files In Submission

Name View Source Status
0001104659-11-062750-index-headers.html Edgar Link pending
0001104659-11-062750-index.html Edgar Link pending
0001104659-11-062750.txt Edgar Link pending
0001104659-11-062750-xbrl.zip Edgar Link pending
a11-25007_110q.htm Edgar Link pending
a11-25007_1ex31d1.htm Edgar Link pending
a11-25007_1ex31d2.htm Edgar Link pending
a11-25007_1ex32d1.htm Edgar Link pending
a11-25007_1ex32d2.htm Edgar Link pending
bpax-20110930.xml Edgar Link completed
bpax-20110930.xsd Edgar Link pending
bpax-20110930_cal.xml Edgar Link unprocessable
bpax-20110930_def.xml Edgar Link unprocessable
bpax-20110930_lab.xml Edgar Link unprocessable
bpax-20110930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending